Caraballo Galva LD, Jiang X, Hussein MS, Zhang H, et al. Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinoma. Hepatology 2021 Dec 12. doi: 10.1002/hep.32279.
PMID: 34897774